Efavirenz Plasma Concentrations in Portuguese HIV Infected Subjects



S. A. Pereira¹, R. M. Côrte-Real¹, T. Branco², F. Lampreia², I. Germano², U. Caixas² & E. C. Monteiro¹.

¹Faculty of Medical Sciences, Lisbon, Portugal; ²Hospital do Desterro, Lisbon, Portugal.



Background

Variability of efavirenz (EFV) plasma concentrations is multifactorial and could be one of the pharmacological causes of therapeutic failure. It has been shown that EFV plasma concentrations is dependent on P-gp and CYP450 polymorphisms (Fellay et al, 2002, Lancet, 359:30-36) present in different ethnic groups (Ameyaw et al, 2001, Pharmacogenetics, 11: 217-21).

In the present work, EFV plasma concentrations were quantified in Portuguese HIV-1 infected subjects in order to assess its interindividual variability.

Methods

This study included 16 adult subjects receiving 600 mg EFV, once a day, in combination with other antiretroviral drugs, for more than 1 month.

Age Range: 39 ± 2.4 years BMI Range: 23 ± 0.7 Kg/m²

81% of the Individuals were naive (n = 13)

Written informed consent was obtained from all patients in accordance with the Helsinki Declaration and the study was approved by the "Hospital do Desterro" Ethics Committee.

Plasma samples were obtained 8-13 h after EFV administration and were used to measure viral load, CD₄⁺ cell count, EFV concentrations and other laboratory parameters.

EFV plasma concentrations were quantified by HPLC with UV detection.

This method, validated in the Laboratory of Pharmacology was further submitted to an International Quality Control Program (KKGT, The Netherlands).


Correspondence to


Carrespondence to:
Sofia Pereira
Faculty of Medical Sciences, New University of Lisbon
Campo Mártires da Pátria, 130
1169-056 Lisboa, Portugal
e-mail:


Results


Inter-individual Variability in Efavirenz Plasma Concentrations n=16 Mean: 2.10 ± 1.64 µg/mL Maximum: 5.80 µg/mL Minimum: 1.04 µg/mL CV: 55 % Viral loads: < 200 cps/ mL

Efavirenz









Conclusions

From the present results it is concluded that the inter-individual variability observed in EFV plasma levels supports the interest of a concentration-controlled therapy.

These are preliminary results. Inclusion of more subjects and time course of their viral loads are needed to establish reliable correlations.